

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women**  
**Report – April 7, 2018**  
**Visit Cutoff Date: April 6, 2018**  
**Table 4 – Progression to Step 2 by Site**

	<b>Overall</b>	<b>Baylor</b>	<b>Blantyre</b>	<b>Botha's Hill</b>	<b>DTTC-SU</b>
Total Participants Enrolled <sup>1</sup>	107	0	0	0	0
Participants who have been enrolled for 6 weeks or received injection <sup>2</sup>	61	0	0	0	0
Progressed to Step 2	58/61 (95.1%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Progression Status Pending	2/61 (3.3%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Did Not Progress to Step 2	1/61 (1.6%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Permanently discontinued from the study product	0/61 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Terminated from the study	1/61 (1.6%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Permanently discontinued from the study product first and then terminated from the study	0/61 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)

<sup>1</sup> Inappropriately enrolled participants are excluded.

<sup>2</sup> Participants who did not progress to Step 2 due to HIV infection are not included.

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for  
Pre-Exposure Prophylaxis in HIV-Uninfected Women  
Report – April 7, 2018  
Visit Cutoff Date: April 6, 2018  
Table 4 – Progression to Step 2 by Site**

	<b>Emavundleni</b>	<b>Gaborone</b>	<b>Isipingo</b>	<b>Kisumu</b>	<b>Lilongwe</b>
Total Participants Enrolled <sup>1</sup>	0	7	0	0	0
Participants who have been enrolled for 6 weeks or received injection <sup>2</sup>	0	3	0	0	0
Progressed to Step 2	0/0 (-%)	2/3 (66.7%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Progression Status Pending	0/0 (-%)	1/3 (33.3%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Did Not Progress to Step 2	0/0 (-%)	0/3 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Permanently discontinued from the study product	0/0 (-%)	0/3 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Terminated from the study	0/0 (-%)	0/3 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Permanently discontinued from the study product first and then terminated from the study	0/0 (-%)	0/3 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)

<sup>1</sup> Inappropriately enrolled participants are excluded.

<sup>2</sup> Participants who did not progress to Step 2 due to HIV infection are not included.

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for  
Pre-Exposure Prophylaxis in HIV-Uninfected Women  
Report – April 7, 2018  
Visit Cutoff Date: April 6, 2018  
Table 4 – Progression to Step 2 by Site**

	<b>MU-JHU</b>	<b>Parirenyatwa</b>	<b>Seke South</b>	<b>Soweto</b>	<b>Spilhaus</b>
Total Participants Enrolled <sup>1</sup>	0	12	0	32	0
Participants who have been enrolled for 6 weeks or received injection <sup>2</sup>	0	4	0	26	0
Progressed to Step 2	0/0 (-%)	4/4 (100.0%)	0/0 (-%)	25/26 (96.2%)	0/0 (-%)
Progression Status Pending	0/0 (-%)	0/4 (0.0%)	0/0 (-%)	0/26 (0.0%)	0/0 (-%)
Did Not Progress to Step 2	0/0 (-%)	0/4 (0.0%)	0/0 (-%)	1/26 (3.8%)	0/0 (-%)
Permanently discontinued from the study product	0/0 (-%)	0/4 (0.0%)	0/0 (-%)	0/26 (0.0%)	0/0 (-%)
Terminated from the study	0/0 (-%)	0/4 (0.0%)	0/0 (-%)	1/26 (3.8%)	0/0 (-%)
Permanently discontinued from the study product first and then terminated from the study	0/0 (-%)	0/4 (0.0%)	0/0 (-%)	0/26 (0.0%)	0/0 (-%)

<sup>1</sup> Inappropriately enrolled participants are excluded.

<sup>2</sup> Participants who did not progress to Step 2 due to HIV infection are not included.

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for  
Pre-Exposure Prophylaxis in HIV-Uninfected Women  
Report – April 7, 2018  
Visit Cutoff Date: April 6, 2018  
Table 4 – Progression to Step 2 by Site**

	<b>St.Mary's Clinic</b>	<b>Swaziland</b>	<b>UVRI-IAVI</b>	<b>Verulam</b>	<b>Ward 21</b>
Total Participants Enrolled <sup>1</sup>	12	0	0	0	29
Participants who have been enrolled for 6 weeks or received injection <sup>2</sup>	3	0	0	0	17
Progressed to Step 2	3/3 (100.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	17/17 (100.0%)
Progression Status Pending	0/3 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/17 (0.0%)
Did Not Progress to Step 2	0/3 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/17 (0.0%)
Permanently discontinued from the study product	0/3 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/17 (0.0%)
Terminated from the study	0/3 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/17 (0.0%)
Permanently discontinued from the study product first and then terminated from the study	0/3 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/17 (0.0%)

<sup>1</sup> Inappropriately enrolled participants are excluded.

<sup>2</sup> Participants who did not progress to Step 2 due to HIV infection are not included.

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women**  
**Report – April 7, 2018**  
**Visit Cutoff Date: April 6, 2018**  
**Table 4 – Progression to Step 2 by Site**

	<b>Zengeza</b>
Total Participants Enrolled <sup>1</sup>	15
Participants who have been enrolled for 6 weeks or received injection <sup>2</sup>	8
Progressed to Step 2	7/8 (87.5%)
Progression Status Pending	1/8 (12.5%)
Did Not Progress to Step 2	0/8 (0.0%)
Permanently discontinued from the study product	0/8 (0.0%)
Terminated from the study	0/8 (0.0%)
Permanently discontinued from the study product first and then terminated from the study	0/8 (0.0%)

<sup>1</sup> Inappropriately enrolled participants are excluded.

<sup>2</sup> Participants who did not progress to Step 2 due to HIV infection are not included.